Showing 4761-4770 of 9330 results for "".
- Physician Pessimism, Dissatisfaction Highhttps://practicaldermatology.com/news/20120928-physician_pessimism_dissatisfaction_high/2459726/More than half of American physicians participating in a recent survey say they plan to significantly modify their practice patterns over the next one to three years, new research suggests. They report plans to cut back on patients seen, work part-time, switch to concierge medicine, retire, or take…
- Lucid, Inc. Now Named Caliber IDhttps://practicaldermatology.com/news/20120926-lucid_inc_now_named_caliber_id/2459729/Lucid, Inc. announced that it is now operating under a new company name, Caliber Imaging & Diagnostics, Inc., or Caliber ID. Caliber ID has created an entirely new class of tools enabling physicians to image and diagnose skin disease in real time without a biopsy. These devices using Caliber ID's r…
- New Practice Offers Personalized Procedureshttps://practicaldermatology.com/news/20120926-new_practice_offers_personalized_procedures/2459730/Dermatologist Candace Thornton Spann, MD, FAAD, and plastic surgeon Marvin Spann, MD, established a joint practice, Couture Dermatology & Plastic Surgery. The practice, which opens October 1, will offer custom-tailored treatments for all ethnicities, ages, and skin types. The office is located at 2…
- Provectus Pharmaceuticals to Present Data on PV-10https://practicaldermatology.com/news/20120918-provectus_pharmaceuticals_to_present_data_on_pv-10/2459733/Provectus Pharmaceuticals, Inc. announced that final efficacy data from its Phase II trial of PV-10 in patients with Stage III-IV melanoma will be presented, including response rate and time-to-event (progression free survival and overall survival), at the ESMO 2012 (European Society for Medical On…
- p53R2 Regulates Proliferation and Chemosensitivity in Melanomahttps://practicaldermatology.com/news/20120918-p53r2_regulates_proliferation_and_chemosensitivity_in_melanoma/2459734/Expression of p53R2 significantly correlates with the depth of invasion and the tumor stage in melanoma, new research shows. (J Dermatol Sci; 68(1):19-24) Furthermore, use of siRNA targeting p53R2 successfully knocked down p53R2 and significantly inhibited the growth of KHm5 and 6 cells. The degree…
- Colorescience's Diane Ranger to Receive Innovators in Dermatology Award at CSF 2012https://practicaldermatology.com/news/20120917-coloresciences_diane_ranger_to_receive_innovators_in_dermatology_award_at_csf_2012/2459738/Diane Ranger, Founder and President of Colorescience Mineral Makeup, and acknowledged inventor of mineral makeup, will receive the "Innovators in Dermatology Award" at Cosmetic Surgery Forum 2012 in Las Vegas, November 29 thru December 1. Early bird registration for the event closes September 18. M…
- NeoStrata Teams with Avon on Anew Clinical Pro Line Eraserhttps://practicaldermatology.com/news/20120917-neostrata_teams_with_avon_on_anew_clinical_pro_line_eraser/2459739/In collaboration with NeoStrata Company, Avon has expanded its Anew line with products featuring A-F33, a newly discovered anti-aging molecule. In Anew Clinical Pro Line Eraser, A-F33 (Aminofill-33) is said to deactivate critical collagen blocking in skin cells to encourage formation of collagen. A…
- CMS Provider Call Today on EHRshttps://practicaldermatology.com/news/20120913-cms_provider_call_today_on_ehrs/2459740/The Centers for Medicare and Medicaid Services will host a 90-minute National Provider Call today, Sept. 13, to discuss the final rule for the Stage 2 electronic health records meaningful use program. The call is free, but prior registration is required. Registration closes at noon EST today or whe…
- Direct-to-Consumer Pharmaceutical Advertising: Minimizing Risks?https://practicaldermatology.com/news/20120912-letter_to_editor_discusses_changes_in_direct-to-consumer_pharmaceutical_advertising/2459741/When prescription drugs switch to over-the-counter status, regulatory oversight of their advertising shifts to the Federal Trade Commission (FTC), potentially leading to reduced focus on warnings about risks and side effects, a new report suggests. While the FDA regulates prescription drug advertis…
- Valeant Acquires Medicis Pharmaceutical Corp. for $2.6 Billionhttps://practicaldermatology.com/news/20120904-valeant_acquires_medicis_pharmaceutical_for_26_billion/2459743/Valeant Pharmaceuticals announced an agreement to acquire Medicis Pharmaceutical for $44 per share in cash, in a deal worth approximately $2.6 billion. The transaction is expected to close in the first half of 2013 and has been approved by each company's board of directors. The combined operations …